Bushen Jianpi Huoxue Recipe is closely related to the target of histone demethylase JMJD2B in promoting osteogenic differentiation in osteoporosis: an in vitro cell experimental verification

doi:10.12307/2022.904

Abstract

Abstract: BACKGROUND: Bushen Jianpi Huoxue Recipe is an empirical prescription commonly used in the treatment of osteoporosis. However, its potential molecular mechanism needs to be further explored.
OBJECTIVE: To explore the potential molecular mechanism of Bushen Jianpi Huoxue Recipe in the treatment of osteoporosis based on network pharmacology, and to verify the possibility of its effect through histone methylation modification.
METHODS: Based on the network pharmacology, the active drug components and action targets of Bushen Jianpi Huoxue Recipe were screened from relevant database using relevant software, and the targets of osteoporosis-related diseases were obtained. The intersected targets were obtained and identified as the potential targets of Bushen Jianpi Huoxue Recipe in the treatment of osteoporosis. The drug component-target network was constructed by String and Cytoscape software, and the core targets were screened out. The functions and genes related to histone modification were extracted based on the results of GO biological analysis, and the target genes related to histone modification were screened from the core targets. Literature analysis was performed to indicate the possible biological role of target genes in osteoporosis and histone modification. In vitro cell experiments were conducted to verify the effect of Bushen Jianpi Huoxue Recipe on osteogenic differentiation in the treatment of osteoporosis via the regulation of histone demethylase JMJD2B that is closely related to the target.
RESULTS AND CONCLUSION: A total of 118 active drug components related to osteoporosis were identified, with 165 corresponding targets. The core targets were IL6, TP53, FOS, JUN, STAT3, RELA, CCND1, MYC, MAPK1, MAPK8, MAPK14, VEGFA, AKT1, ESR1, TNF, NR3C1 and so on. GO biological function analysis showed that the biological functions such as drug response, nutrition level response, oxidative stress response, steroid hormone response, transcriptional regulation, transcription factor binding, phosphatase binding, protease binding, and steroid hormone receptor activity were closely related to the common targets. The core targets such as MAPK8, VEGFA and TP53 were related to histone modification; luteolin, quercetin, and kaempferol might be the main drug components affecting histone modification in the treatment of osteoporosis. Results from the in vitro cell experiment revealed that the expression of osteogenesis-related alkaline phosphatase, JMJD2B and RUNX2 protein increased significantly in rat bone marrow mesenchymal stem cells treated with Bushen Jianpi Huoxue Recipe. Histone demethylase JMJD2B, which is closely related to the pharmacological target of Bushen Jianpi Huoxue Recipe, might promote osteogenic differentiation in the treatment of osteoporosis.

Key words: histone demethylase, osteoporosis, JMJD2B, osteogenic differentiation, network pharmacology

CLC Number:

Luo Zhen, Huang Yuxi, Chai Shengting, Li Feilong, Chen Qunqun. Bushen Jianpi Huoxue Recipe is closely related to the target of histone demethylase JMJD2B in promoting osteogenic differentiation in osteoporosis: an in vitro cell experimental verification[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(29): 4643-4650.

Figures/Tables 12

References

[1] 姜涛,邵敏,陈庆真,等.ERα-AMPK-Sirt1信号通路在骨质疏松症中的作用[J].中国骨质疏松杂志,2019,25(8):1166-1171.
[2] 肖豪,刘静,周君.脉冲电磁场治疗绝经后骨质疏松症的研究进展[J].中国组织工程研究,2022,26(8):1323-1329.
[3] STROUP J, KANE MP, ABU-BAKER AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008;65(6):532-539.
[4] 吴海洋,索欢,王平.绝经后骨质疏松症的临床中药治疗进展[J].中国骨质疏松杂志,2015,21(2):241-244.
[5] 柴生颋,谢平金,方鸿星,等.补肾中药骨康方治疗肾阳虚型绝经后骨质疏松症疗效及对E2、OPG及IGF-1影响[J].辽宁中医药大学学报,2018,20(7):170-173.
[6] 柴爽,黄佳纯,王吉利,等.补肾健脾活血方对大鼠绝经后骨质疏松症的防治作用[J].中成药,2019,41(9):2213-2216.
[7] 柴生颋,谢平金,万雷,等.补肾健脾活血方含药血清对UMR106细胞成骨分化和骨形成相关蛋白的影响[J].中国骨质疏松杂志,2018,24(3):361-365.
[8] 世界中医药学会联合会.网络药理学评价方法指南[J].世界中医药,2021,16(4): 527-532.
[9] 申丽莎,杨堃,蒋成英,等.参仙片治疗骨质疏松症作用机制的网络药理学研究[J].中国药业,2021,30(18):32-36.
[10] 李伟,李春根,穆晓红,等.基于网络药理学预测金匮肾气丸治疗骨质疏松症的作用机制[J].世界中医药,2021,16(22):3285-3291,3297.
[11] 温明韬,梁学振,李嘉程,等.基于网络药理学与分子对接技术探讨六味地黄丸抗骨质疏松症的机制研究[J].中国骨质疏松杂志,2021,27(8):1129-1134,1153.
[12] 张洁帆,许坤,陈元川,等.芪骨胶囊治疗绝经后骨质疏松症的分子机制[J].中国骨质疏松杂志,2021,27(8):1093-1100.
[13] 肖方骏,陈树东,栾继耀,等.丹参干预骨质疏松症：网络药理学解释的作用机制[J].中国组织工程研究,2021,25(5):772-778.
[14] 郭承,张颖,唐宏宇,等.绝经后骨质疏松症患者骨组织JMJD2A、JMJD2B表达变化及意义[J].山东医药,2016,56(16):37-39.
[15] 徐叔云,卞如濂,陈修.药理实验方法学[M].北京:人民卫生出版社,1982.
[16] 蔡鹏,朱绍兴,苏一鸣,等.全骨髓贴壁法分离培养大鼠骨髓间充质干细胞及其诱导分化[J].中国组织工程研究与临床康复,2009,13(36):7073-7077.
[17] 中华中医药学会.绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版)[J].中医正骨,2020,32(2):1-13.
[18] 王博深,鲍婷婷,任风英,等.补肾健脾活血法治疗中老年原发性骨质疏松症Meta分析[J].中国骨质疏松杂志,2021,27(6):824-830.
[19] 王磊,沙湖,王翠平,等.补肾活血汤治疗膝骨关节炎合并骨质疏松症疗效及对骨代谢标志物水平的影响[J].中华中医药学刊,2021,39(6):225-228.
[20] 乔立红,徐慧连,王小伟.补肾健脾活血方联合八段锦对老年女性骨质疏松症患者血清钙、磷、25羟维生素D及骨密度的影响[J].新中医,2021,53(19):122-125.
[21] 王凡,黄宏兴,王吉利,等.补肾健脾活血方干预过表达DKK1骨细胞对细胞活性及BMP2的影响[J].中国骨质疏松杂志,2017,23(6):711-714,718.
[22] JURUENA MF, GADELRAB R, CLEARE AJ, et al. Epigenetics: A missing link between early life stress and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110231.
[23] TORRES IO, FUJIMORI DG. Functional coupling between writers, erasers and readers of histone and DNA methylation. Curr Opin Struct Biol. 2015;35:68-75.
[24] 王维,赵学千,贾育松,等.绝经后骨质疏松症发病机制的表观遗传学研究进展[J].中国骨质疏松杂志,2020,26(8):1235-1240.
[25] 孙文熙,刘海全,温俊茂,等.基于表观遗传探讨中医药防治肾虚型骨质疏松症研究现状[J].时珍国医国药,2020,31(5):1209-1211.
[26] SUN J, DONG Z, ZHANG Y, et al. Osthole improves function of periodontitis periodontal ligament stem cells via epigenetic modification in cell sheets engineering. Sci Rep. 2017;7(1):5254.
[27] XU R, ZHANG C, SHIN DY, et al. c-Jun N-Terminal Kinases (JNKs) Are Critical Mediators of Osteoblast Activity In Vivo. J Bone Miner Res. 2017;32(9):1811-1815.
[28] LIU Y, BERENDSEN AD, JIA S, et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest. 2012;122(9):3101-3113.
[29] YU T, YOU X, ZHOU H, et al. MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA. Aging (Albany NY). 2020;12(10):9500-9514.
[30] MOLCHADSKY A, SHATS I, GOLDFINGER N, et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008;3(11):e3707.
[31] YU T, YOU X, ZHOU H, et al. p53 plays a central role in the development of osteoporosis. Aging (Albany NY). 2020;12(11):10473-10487.
[32] ZHOU XP, LI QW, SHU ZZ, et al. TP53-mediated miR-2861 promotes osteogenic differentiation of BMSCs by targeting Smad7. Mol Cell Biochem. 2021 Oct 28. doi: 10.1007/s11010-021-04276-1. Online ahead of print.
[33] HE Y, DE CASTRO LF, SHIN MH, et al. p53 loss increases the osteogenic differentiation of bone marrow stromal cells. Stem Cells. 2015;33(4):1304-1319.
[34] ARTIGAS N, GÁMEZ B, CUBILLOS-ROJAS M, et al. p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation. Cell Death Differ. 2017; 24(12):2022-2031.
[35] XIA C, JIANG T, WANG Y, et al. The p53/miR-145a Axis Promotes Cellular Senescence and Inhibits Osteogenic Differentiation by Targeting Cbfb in Mesenchymal Stem Cells. Front Endocrinol (Lausanne). 2021;11:609186.
[36] YU T, WANG Z, YOU X, et al. Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53. Aging (Albany NY). 2020;12(11):10359-10369.
[37] 尚丹,王辉,韩晔,等.木犀草素对小鼠体外培养前成骨细胞MC3T3-E1增殖、分化、矿化和Wnt通路的影响[J].蚌埠医学院学报,2017,42(1):44-47.
[38] WANG N, WANG L, YANG J, et al. Quercetin promotes osteogenic differentiation and antioxidant responses of mouse bone mesenchymal stem cells through activation of the AMPK/SIRT1 signaling pathway. Phytother Res. 2021 Jan 9. doi: 10.1002/ptr.7010. Online ahead of print.
[39] 崔琳娜,蒋校文,黄华庆,等.山奈酚通过mTORC1信号促进牵张力下小鼠骨髓间充质细胞成骨分化机制研究[J].口腔疾病防治,2021,29(4):234-240.
[40] VARLEY KE, GERTZ J, BOWLING KM, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 2013;23(3):555-567.
[41] KAWAI T, RICHARDS JS, SHIMADA M. The Cell Type-Specific Expression of Lhcgr in Mouse Ovarian Cells: Evidence for a DNA-Demethylation-Dependent Mechanism. Endocrinology. 2018;159(5):2062-2074.
[42] SHI L, SUN L, LI Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(18):7541-7546.
[43] YE L, FAN Z, YU B, et al. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell. 2012;11(1):50-61.
[44] DENG P, YUAN Q, CHENG Y, et al. Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging. Cell Stem Cell. 2021; 28(6):1057-1073.e7.
[45] 郭海,王海彬,苟凌云,等.仙灵骨葆胶囊对去势大鼠骨组织ERα、JMJD2B、Runx2和ALP表达的影响[J].中国骨质疏松杂志,2018,24(12):1568-1572.
[46] WU MC, CHENG HH, YEH TS, et al. KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis. Cell Death Dis. 2019;10(2):68.
[47] LIU OH, KIEMA M, BETER M, et al. Hypoxia-Mediated Regulation of Histone Demethylases Affects Angiogenesis-Associated Functions in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2020;40(11):2665-2677.
[48] SUZUKI N, JOHMURA Y, WANG TW, et al. TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis. Autophagy. 2021;17(11):3776-3793.
[49] JOHMURA Y, MAEDA I, SUZUKI N, et al. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. J Clin Invest. 2018;128(12):5603-5619.
[50] BANNISTER AJ, KOUZARIDES T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381-395.
[51] STEWART MD, LI J, WONG J. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol. 2005;25(7):2525-2538.